comparemela.com
Home
Live Updates
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023 : comparemela.com
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023
This new post hoc analysis of the Phase 3 EMERALD trial evaluatedelacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations.This analysisshows a clinically meaningful
Related Keywords
United States
,
Elcin Barker Ergun
,
Menarini Stemline
,
Menarini Group
,
Elacestrant Clinical Development Program
,
Ut Health San Antonio
,
Menarini Group Stemline Therapeutic
,
Md Anderson Cancer Center
,
Stemline Therapeutics Inc
,
Stemline Therapeutics
,
Antonio Breast Cancer Symposium
,
Virginia Kaklamani
,
San Antonio
,
Safety Information
,
Stemline Therapeutic
,
Fetal Toxicity
,
comparemela.com © 2020. All Rights Reserved.